Moderna faces both patent lawsuits and backlash over vaccine trials but continues towards innovation in the mRNA sphere. A $5 billion patent lawsuit has been launched while the company has also made a breakthrough in its mRNA cancer vaccine, showing a halved risk of melanoma recurrence with Keytruda. Meanwhile, due to anti-vaccine sentiment in the US, Moderna is curbing investment in vaccine trials. In brighter news, their mRNA cancer vaccine shows protection at its 5-year follow up, according to both Moderna and Merck. CEPI is providing funding for Phase 3 Trials for Moderna’s Pandemic Influenza Candidate. However, Bayer is suing COVID vaccine makers over alleged mRNA infringement. Despite these mixed developments, the Moderna stock surged by 36.7% displaying positive investor outlook. Strikingly, Moderna unveiled they are refocusing on their rare disease pipeline while evolving leadership, promising noteworthy future developments. Furthermore, promising efficacy results have emerged from Moderna's mRNA flu vaccine trial. Yet, amid all this, the company has decided to scrap its mRNA vaccine for congenital CMV due to phase III failure, indicating a potential strategic transformation.
Moderna MRNA News Analytics from Fri, 02 May 2025 07:00:00 GMT to Sat, 07 Feb 2026 10:05:26 GMT -
Rating 3
- Innovation 7
- Information 5
- Rumor 6
